Literature DB >> 28811691

Association of Prooxidant-Antioxidant Balance with Clinical and Laboratory Parameters and Its Relation to Different Drug Regimens in Polycystic Ovary Syndrome Women with Normal BMI.

Niloofar Heshmati1, Shoaleh Shahgheibi2, Bahram Nikkhoo3, Sabrieh Amini1, Mohammad Abdi4,5.   

Abstract

Polycystic ovarian syndrome is one of the most common hormonally leading cause infertility disorders. The effect of oxidant-antioxidant imbalance on disease progression has been studied in many disorders. The present study was aimed to evaluate prooxidant-antioxidant balance (PAB) in patients with polycystic ovarian syndrome compared to healthy subjects. We also studied the possible effect of treatment with available drugs on serum PAB. In this case-control study 100 polycystic ovary syndrome (PCOS) patients and 100 healthy individuals were enrolled in the study. The laboratory features of patients and controls like as serum LH and FSH concentration and hematological examinations were collected. PAB was evaluated by a colorimetric method. Serum PAB value was significantly higher before treatment compared to after treatment and healthy subjects. PAB values were also higher in subjects with irregular menstrual cycle compared to normal subjects. Our results represented that serum PAB values has an indirect significant correlation with serum LH concentration. We also found that drugs regimen containing spironolactone effectively reduced the serum PAB values. Our results showed that PCOS patients had increased level of PAB and treatment with spironolactone mainly decreases the level of serum PAB. Our results indicate that the measurements of PAB may be used as a potential laboratory marker for assessment of PCOS patients.

Entities:  

Keywords:  Follicle stimulating hormone; Luteinizing hormone; Polycystic ovarian syndrome; Prooxidant–antioxidant balance; Spironolactone; Treatment

Year:  2016        PMID: 28811691      PMCID: PMC5539008          DOI: 10.1007/s12291-016-0613-6

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  44 in total

1.  A novel assay for the evaluation of the prooxidant-antioxidant balance, before and after antioxidant vitamin administration in type II diabetes patients.

Authors:  Daryoush Hamidi Alamdari; Konstantinos Paletas; Theodosia Pegiou; Maria Sarigianni; Christina Befani; George Koliakos
Journal:  Clin Biochem       Date:  2006-11-21       Impact factor: 3.281

2.  Nitric oxide and fibrinogen in polycystic ovary syndrome: associations with insulin resistance and obesity.

Authors:  A P Nácul; C D Andrade; P Schwarz; P I Homem de Bittencourt; P M Spritzer
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2006-10-17       Impact factor: 2.435

3.  Progesterone alleviates acute brain injury via reducing apoptosis and oxidative stress in a rat experimental subarachnoid hemorrhage model.

Authors:  Jing Cai; Shenglong Cao; Jingyin Chen; Feng Yan; Gao Chen; Yuying Dai
Journal:  Neurosci Lett       Date:  2015-06-20       Impact factor: 3.046

4.  Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients.

Authors:  Arpita Chakraborty; Subhankar Chowdhury; Maitree Bhattacharyya
Journal:  Diabetes Res Clin Pract       Date:  2010-12-13       Impact factor: 5.602

5.  Evidence for heterogeneous etiologies of adrenal dysfunction in polycystic ovary syndrome.

Authors:  F Gonzalez; L Chang; T Horab; R A Lobo
Journal:  Fertil Steril       Date:  1996-09       Impact factor: 7.329

6.  Non-steroidal antiestrogens induce apoptosis in HL60 and MOLT3 leukemic cells; involvement of reactive oxygen radicals and protein kinase C.

Authors:  T Hayon; A Dvilansky; L Oriev; I Nathan
Journal:  Anticancer Res       Date:  1999 May-Jun       Impact factor: 2.480

7.  Combination clomiphene citrate and antioxidant therapy for idiopathic male infertility: a randomized controlled trial.

Authors:  Hussein Ghanem; Osama Shaeer; Amgad El-Segini
Journal:  Fertil Steril       Date:  2009-03-06       Impact factor: 7.329

8.  Oxidative stress markers in young patients with polycystic ovary syndrome, the relationship between insulin resistances.

Authors:  M Karadeniz; M Erdoğan; S Tamsel; A Zengi; G E Alper; O Cağlayan; F Saygili; C Yilmaz
Journal:  Exp Clin Endocrinol Diabetes       Date:  2008-04       Impact factor: 2.949

9.  Spironolactone and dimethylsulfoxide effect on glucose metabolism and oxidative stress markers in polycystic ovarian syndrome rat model.

Authors:  A Dăneasă; C Cucolaș; M Furcea; P Bolfa; S Dudea; D Olteanu; M C Alupei; A Mureșan; G A Filip
Journal:  Exp Clin Endocrinol Diabetes       Date:  2014-03-18       Impact factor: 2.949

10.  Oxidative stress but not endothelial dysfunction exists in non-obese, young group of patients with polycystic ovary syndrome.

Authors:  Naci Kemal Kuşçu; Ahmet Var
Journal:  Acta Obstet Gynecol Scand       Date:  2009       Impact factor: 3.636

View more
  3 in total

1.  Serum ischemia modified albumin is a possible new marker of oxidative stress in phenylketonuria.

Authors:  Fatemeh Keshavarzi; Mohsen Rastegar; Mahmood Vessal; Gholamreza Rafiei Dehbidi; Marjan Khorsand; Amir Hossein Ganjkarimi; Mohammad Ali Takhshid
Journal:  Metab Brain Dis       Date:  2017-12-21       Impact factor: 3.584

2.  Evaluation of a Summary Score for Dyslipidemia, Oxidative Stress and Inflammation (the Doi Score) in Women with Polycystic Ovary Syndrome and its Relationship with Obesity.

Authors:  Iva Perović Blagojević; Svetlana Ignjatović; Djuro Macut; Jelena Kotur-Stevuljević; Ivana Božić-Antić; Jelena Vekić; Jelica Bjekić-Macut; Biljana Kastratović-Kotlica; Zoran Andrić; Dušan Ilić
Journal:  J Med Biochem       Date:  2018-12-01       Impact factor: 3.402

3.  Alteration in Prooxidant-antioxidant Balance Associated with Selenium Concentration in Patients with Congenital Hypothyroidism.

Authors:  Shilan Rostami; Asadollah Fathollahpour; Mohammad Abdi; Kejal Naderi
Journal:  J Med Biochem       Date:  2018-07-01       Impact factor: 3.402

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.